These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27282309)

  • 21. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.
    Righi L; Duregon E; Vatrano S; Izzo S; Giorcelli J; Rondón-Lagos M; Ascoli V; Ruffini E; Ventura L; Volante M; Papotti M; Scagliotti GV
    J Thorac Oncol; 2016 Nov; 11(11):2006-2017. PubMed ID: 27422796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A molecular phenotypic map of malignant pleural mesothelioma.
    Di Genova A; Mangiante L; Sexton-Oates A; Voegele C; Fernandez-Cuesta L; Alcala N; Foll M
    Gigascience; 2022 Dec; 12():. PubMed ID: 36705549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma.
    Shimizu D; Ishibashi M; Yamada T; Toda Y; Hosogi S; Ashihara E
    Cancer Genomics Proteomics; 2024; 21(2):158-165. PubMed ID: 38423601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
    Johnson TG; Schelch K; Cheng YY; Williams M; Sarun KH; Kirschner MB; Kao S; Linton A; Klebe S; McCaughan BC; Lin RCY; Pirker C; Berger W; Lasham A; van Zandwijk N; Reid G
    J Thorac Oncol; 2018 Feb; 13(2):258-272. PubMed ID: 29113949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.
    Borczuk AC; Pei J; Taub RN; Levy B; Nahum O; Chen J; Chen K; Testa JR
    Cancer Biol Ther; 2016; 17(3):328-35. PubMed ID: 26853494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
    Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
    Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genes and Pathways Involved in the Progression of Malignant Pleural Mesothelioma: A Meta-analysis of Genome-Wide Expression Studies.
    Mejia-Garcia A; Bonilla DA; Ramirez CM; Escobar-Díaz FA; Combita AL; Forero DA; Orozco C
    Biochem Genet; 2024 Feb; 62(1):352-370. PubMed ID: 37347449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ADAM10 mediates malignant pleural mesothelioma invasiveness.
    Sépult C; Bellefroid M; Rocks N; Donati K; Gérard C; Gilles C; Ludwig A; Duysinx B; Noël A; Cataldo D
    Oncogene; 2019 May; 38(18):3521-3534. PubMed ID: 30651596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
    de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
    Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment.
    Sculco M; La Vecchia M; Aspesi A; Pinton G; Clavenna MG; Casalone E; Allione A; Grosso F; Libener R; Muzio A; Rena O; Baietto G; Parini S; Boldorini R; Giachino D; Papotti M; Scagliotti GV; Migliore E; Mirabelli D; Moro L; Magnani C; Ferrante D; Matullo G; Dianzani I
    Eur J Cancer; 2022 Mar; 163():44-54. PubMed ID: 35032816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma.
    Kato T; Lee D; Wu L; Patel P; Young AJ; Wada H; Hu HP; Ujiie H; Kaji M; Kano S; Matsuge S; Domen H; Kanno H; Hatanaka Y; Hatanaka KC; Kaga K; Matsui Y; Matsuno Y; De Perrot M; Yasufuku K
    Int J Oncol; 2016 Dec; 49(6):2411-2420. PubMed ID: 27840913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene-asbestos interaction in malignant pleural mesothelioma susceptibility.
    Tunesi S; Ferrante D; Mirabelli D; Andorno S; Betti M; Fiorito G; Guarrera S; Casalone E; Neri M; Ugolini D; Bonassi S; Matullo G; Dianzani I; Magnani C
    Carcinogenesis; 2015 Oct; 36(10):1129-35. PubMed ID: 26139392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
    Quispel-Janssen JM; Badhai J; Schunselaar L; Price S; Brammeld J; Iorio F; Kolluri K; Garnett M; Berns A; Baas P; McDermott U; Neefjes J; Alifrangis C
    Clin Cancer Res; 2018 Jan; 24(1):84-94. PubMed ID: 29061644
    [No Abstract]   [Full Text] [Related]  

  • 35. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
    Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
    Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma.
    De Rienzo A; Archer MA; Yeap BY; Dao N; Sciaranghella D; Sideris AC; Zheng Y; Holman AG; Wang YE; Dal Cin PS; Fletcher JA; Rubio R; Croft L; Quackenbush J; Sugarbaker PE; Munir KJ; Battilana JR; Gustafson CE; Chirieac LR; Ching SM; Wong J; Tay LC; Rudd S; Hercus R; Sugarbaker DJ; Richards WG; Bueno R
    Cancer Res; 2016 Jan; 76(2):319-28. PubMed ID: 26554828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
    Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis.
    Smeele P; d'Almeida SM; Meiller C; Chéné AL; Liddell C; Cellerin L; Montagne F; Deshayes S; Benziane S; Copin MC; Hofman P; Le Pimpec-Barthes F; Porte H; Scherpereel A; Grégoire M; Jean D; Blanquart C
    Mol Cancer; 2018 Oct; 17(1):148. PubMed ID: 30309369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomics and Functional Genomics of Malignant Pleural Mesothelioma.
    Cakiroglu E; Senturk S
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comprehensive study of alternative splicing in malignant pleural mesothelioma identifies potential therapeutic targets in a new cluster with poor survival.
    Shao MM; Qiao X; Chen QY; Yi FS
    Thorac Cancer; 2022 Aug; 13(16):2318-2330. PubMed ID: 35790883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.